Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Atherosclerosis

ClinicalTrials.gov lists 2,952 trials for Atherosclerosis or a narrower condition beneath it. National Heart, Lung, and Blood Institute (NHLBI) has the most among industry and government lead sponsors, with 96.

MeSH D050197 Cardiovascular Diseases C14
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 146 Phase 1/2 Phase 1/2 63 Phase 2 Phase 2 203 Phase 2/3 Phase 2/3 53 Phase 3 Phase 3 186 Phase 4 Phase 4 264 Not applicable Not applicable 1,010 Observational Observational 1,022 Phase 1 Phase 1 146 Phase 1/2 Phase 1/2 63 Phase 2 Phase 2 203 Phase 2/3 Phase 2/3 53 Phase 3 Phase 3 186 Phase 4 Phase 4 264 Not applicable Not applicable 1,010 Observational Observational 1,022

Trials per phase

1 more section with rows

1,481 of the 2,952 trials are tagged with Atherosclerosis itself; the rest are tagged with a narrower condition beneath it.

Get the Atherosclerosis report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Atherosclerosis trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 6 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access)

Top of scale: 145

1990: 6 trials (Observational 4, Phase 3 1, Phase 2 1) 1991: 8 trials (Observational 7, Phase 4 1) 1992: 7 trials (Observational 7) 1993: 5 trials (Observational 3, Phase 4 1, Phase 1 1) 1994: 5 trials (Observational 4, Phase 2/3 1) 1995: 7 trials (Observational 4, Not applicable 2, Phase 2 1) 1996: 10 trials (Observational 6, Not applicable 2, Phase 4 1, Phase 2/3 1) 1997: 9 trials (Observational 5, Phase 3 3, Phase 2/3 1) 1998: 4 trials (Observational 3, Phase 3 1) 1999: 8 trials (Observational 4, Phase 3 2, Phase 2 1, Phase 1 1) 2000: 30 trials (Observational 15, Not applicable 5, Phase 4 2, Phase 3 4, Phase 2/3 1, Phase 2 2, Phase 1 1) 2001: 32 trials (Observational 19, Not applicable 2, Phase 4 2, Phase 3 2, Phase 2/3 1, Phase 2 5, Phase 1 1) 2002: 25 trials (Observational 10, Not applicable 4, Phase 4 3, Phase 3 1, Phase 2 5, Phase 1/2 1, Phase 1 1) 2003: 59 trials (Observational 23, Not applicable 2, Phase 4 12, Phase 3 13, Phase 2/3 1, Phase 2 5, Phase 1/2 1, Phase 1 2) 2004: 53 trials (Observational 15, Not applicable 6, Phase 4 10, Phase 3 8, Phase 2/3 3, Phase 2 5, Phase 1/2 1, Phase 1 5) 2005: 59 trials (Observational 14, Not applicable 8, Phase 4 13, Phase 3 7, Phase 2/3 2, Phase 2 12, Phase 1 3) 2006: 78 trials (Observational 19, Not applicable 16, Phase 4 12, Phase 3 6, Phase 2/3 1, Phase 2 13, Phase 1/2 3, Phase 1 8) 2007: 96 trials (Observational 31, Not applicable 18, Phase 4 11, Phase 3 10, Phase 2/3 4, Phase 2 8, Phase 1/2 3, Phase 1 11) 2008: 101 trials (Observational 34, Not applicable 19, Phase 4 17, Phase 3 6, Phase 2/3 4, Phase 2 12, Phase 1/2 2, Phase 1 7) 2009: 114 trials (Observational 36, Not applicable 28, Phase 4 18, Phase 3 8, Phase 2/3 4, Phase 2 8, Phase 1/2 6, Phase 1 6) 2010: 106 trials (Observational 36, Not applicable 32, Phase 4 13, Phase 3 5, Phase 2/3 3, Phase 2 8, Phase 1/2 4, Phase 1 5) 2011: 118 trials (Observational 40, Not applicable 36, Phase 4 9, Phase 3 10, Phase 2/3 3, Phase 2 10, Phase 1/2 8, Phase 1 2) 2012: 107 trials (Observational 36, Not applicable 30, Phase 4 13, Phase 3 7, Phase 2/3 2, Phase 2 9, Phase 1/2 3, Phase 1 7) 2013: 105 trials (Observational 32, Not applicable 38, Phase 4 9, Phase 3 2, Phase 2/3 3, Phase 2 10, Phase 1/2 2, Phase 1 9) 2014: 127 trials (Observational 47, Not applicable 51, Phase 4 10, Phase 3 2, Phase 2/3 1, Phase 2 8, Phase 1/2 3, Phase 1 5) 2015: 132 trials (Other 1, Observational 32, Not applicable 52, Phase 4 14, Phase 3 9, Phase 2/3 4, Phase 2 8, Phase 1/2 2, Phase 1 10) 2016: 134 trials (Observational 32, Not applicable 66, Phase 4 12, Phase 3 8, Phase 2/3 1, Phase 2 8, Phase 1/2 4, Phase 1 3) 2017: 143 trials (Observational 40, Not applicable 64, Phase 4 10, Phase 3 10, Phase 2 7, Phase 1/2 2, Phase 1 10) 2018: 135 trials (Observational 40, Not applicable 68, Phase 4 6, Phase 3 5, Phase 2/3 3, Phase 2 5, Phase 1/2 2, Phase 1 6) 2019: 130 trials (Observational 45, Not applicable 55, Phase 4 8, Phase 3 7, Phase 2/3 3, Phase 2 6, Phase 1/2 2, Phase 1 4) 2020: 145 trials (Observational 58, Not applicable 54, Phase 4 12, Phase 3 5, Phase 2/3 1, Phase 2 6, Phase 1/2 3, Phase 1 6) 2021: 145 trials (Observational 58, Not applicable 62, Phase 4 4, Phase 3 9, Phase 2 6, Phase 1/2 1, Phase 1 5) 2022: 133 trials (Observational 48, Not applicable 64, Phase 4 4, Phase 3 6, Phase 2 6, Phase 1 5) 2023: 142 trials (Observational 53, Not applicable 65, Phase 4 12, Phase 3 3, Phase 2 3, Phase 1/2 3, Phase 1 3) 2024: 141 trials (Observational 55, Not applicable 58, Phase 4 10, Phase 3 5, Phase 2/3 1, Phase 2 6, Phase 1/2 1, Phase 1 5) 2025: 127 trials (Observational 41, Not applicable 54, Phase 4 8, Phase 3 11, Phase 2 6, Phase 1/2 1, Phase 1 6)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 122
2025 127
2024 141
2023 142
2022 133
2021 145
2020 145
2019 130
2018 135
2017 143

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 140 trials starting in 2026 and about 130 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 225 trials still running at the 2026-10-09 snapshot; registered median of 27 months across 1,739 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Atherosclerosis trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 146
Phase 1/2 63
Phase 2 203
Phase 2/3 53
Phase 3 186
Phase 4 264
Not applicable 1,010
Observational 1,022
Expanded access 5

How many Atherosclerosis trials are recruiting? (12)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 106
Recruiting 300
Enrolling by invitation 21
Active, not recruiting 114
Available 2

Showing 5 of 12 statuses.

Start your 14-day trial Email me all 12 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Atherosclerosis trials? (11)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Heart, Lung, and Blood Institute (NHLBI) 96
GlaxoSmithKline 32
University Hospital, Angers 28
Boston Scientific Corporation 26
Novartis Pharmaceuticals 25

Showing 5 of 11 sponsors.

Start your 14-day trial Email me all 11 sponsors as a PDF

Which drugs are being tested for Atherosclerosis? (8)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
ATORVASTATIN 35
ROSUVASTATIN 29
SIMVASTATIN 25
Ezetimibe 24
Cilostazol 19

Showing 5 of 8 drugs.

Start your 14-day trial Email me all 8 drugs as a PDF

Interventions as named in the registry (7)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
EC Aspirin 49
Clopidogrel 75 32
Exercise 24
Inclisiran (Leqvio®) 300mg 20
Colchicines 17

Showing 5 of 7 interventions.

Start your 14-day trial Email me all 7 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Atherosclerosis trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Surgical and medical procedures 12,354 6
Cardiac disorders 9,217 5
Nervous system disorders 5,038 6
Infections and infestations 5,034 7
Investigations 4,565 5

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Atherosclerosis? (2,031)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Cardiovascular Risk Assessment Using the Atherosclerotic Cardiovascular Disease Risk Score Model after Continuing or Switching to a Doravirine-Based HIV Treatment Regimen. Journal of acquired immune deficiency syndromes (1999) 2026 Yes
Use of statins and its association with major adverse cardiovascular events with tofacitinib vs TNF inhibitors in patients with rheumatoid arthritis with and without atherosclerotic cardiovascular disease. Annals of the rheumatic diseases 2026 Yes
Evolocumab in Patients without a Previous Myocardial Infarction or Stroke. The New England journal of medicine 2026 Yes
Microplastics and Atherosclerosis: Mechanisms. Annual review of pharmacology and toxicology 2026 Yes
Lipoprotein(a): A Review of Risk Factors, Measurements, and Novel Treatment Modalities. Cardiology in review 2025 Yes

Showing 5 of 2,031 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (1)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages